<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Antibody concentration strata for participants with measurable neutralising antibodies</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th/>
    <th colspan="2" align="left">
     <bold>Participants</bold>
     <hr/>
    </th>
    <th colspan="2" align="left">
     <bold>Neutralising antibodies (IU/mL)</bold>
     <hr/>
    </th>
   </tr>
   <tr>
    <th/>
    <th/>
    <th align="left">n (%, 95% CI)</th>
    <th align="left">Percentage of seropositive participants</th>
    <th align="left">Geometric mean (95% CI)</th>
    <th align="left">Median (IQR)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6" align="left">
     <bold>Seropositive participants (antibody concentration ≥0·5 IU/ml)</bold>
    </td>
   </tr>
   <tr>
    <td colspan="6" align="left">Mali, year 4·5, n=587</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Total</td>
    <td align="left">296 (50·4%, 46·4–54·5)</td>
    <td align="left">100·0%</td>
    <td align="left">1·120 (1·040–1·210)</td>
    <td align="left">0·915 (0·702–1·440)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Low tier</td>
    <td align="left">242 (41·2%)</td>
    <td align="left">81·8%</td>
    <td align="left">0·863 (0·826–0·902)</td>
    <td align="left">0·882 (0·610–1·210)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">High tier</td>
    <td align="left">54 (9·2%)</td>
    <td align="left">18·2%</td>
    <td align="left">3·530 (3·100–4·070)</td>
    <td align="left">2·890 (2·420–4·640)</td>
   </tr>
   <tr>
    <td colspan="6" align="left">Ghana, year 2·3, N=436</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Total</td>
    <td align="left">121 (27·8%, 23·5–32·0)</td>
    <td align="left">100·0%</td>
    <td align="left">1·380 (1·170–1·660)</td>
    <td align="left">1·020 (0·721–2·030)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Low tier</td>
    <td align="left">90 (20·6%)</td>
    <td align="left">74·4%</td>
    <td align="left">0·854 (0·792–0·922)</td>
    <td align="left">0·765 (0·610–1·210)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">High tier</td>
    <td align="left">31 (7·1%)</td>
    <td align="left">25·6%</td>
    <td align="left">5·560 (4·110–7·790)</td>
    <td align="left">4·080 (2·890–8·160)</td>
   </tr>
   <tr>
    <td colspan="6" align="left">Ghana, year 6·0, n=436</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Total</td>
    <td align="left">188 (43·1%, 38·5–47·8)</td>
    <td align="left">100·0%</td>
    <td align="left">1·790 (1·550–2·080)</td>
    <td align="left">1·440 (0·854–2·870)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Low tier</td>
    <td align="left">110 (25·2%)</td>
    <td align="left">58·5%</td>
    <td align="left">0·915 (0·856–0·978)</td>
    <td align="left">0·911 (0·647–1·210)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">High tier</td>
    <td align="left">78 (17·9%)</td>
    <td align="left">41·5%</td>
    <td align="left">4·610 (3·810–5·670)</td>
    <td align="left">2·890 (2·350–7·800)</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <bold>Borderline participants (measurable antibody concentration &lt;0·5 IU/ml)</bold>
    </td>
   </tr>
   <tr>
    <td colspan="2" align="left">Mali, year 4·5</td>
    <td align="left">113 (19·3%, 16·1–22·4)</td>
    <td align="left">NA</td>
    <td align="left">0·335 (0·318–0·353)</td>
    <td align="left">0·361 (0·271–0·453)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Ghana, year 2·3</td>
    <td align="left">51 (11·7%, 8·7–14·7)</td>
    <td align="left">NA</td>
    <td align="left">0·359 (0·337–0·382)</td>
    <td align="left">0·381 (0·312–0·430)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Ghana, year 6·0</td>
    <td align="left">35 (8·0%, 5·5–10·6)</td>
    <td align="left">NA</td>
    <td align="left">0·334 (0·309–0·361)</td>
    <td align="left">0·361 (0·302–0·383)</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <bold>Broadly seropositive participants (all participants with a measurable antibody concentration)</bold>
    </td>
   </tr>
   <tr>
    <td colspan="2" align="left">Mali, year 4·5</td>
    <td align="left">409 (69·7%, 66·0–73·4)</td>
    <td align="left">NA</td>
    <td align="left">0·801 (0·742–0·865)</td>
    <td align="left">0·721 (0·457–1·220)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Ghana, year 2·3</td>
    <td align="left">172 (39·4%, 34·9–44·0)</td>
    <td align="left">NA</td>
    <td align="left">0·926 (0·796–1·090)</td>
    <td align="left">0·721 (0·455–1·400)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Ghana, year 6·0</td>
    <td align="left">223 (51·1%, 46·5–55·8)</td>
    <td align="left">NA</td>
    <td align="left">1·380 (1·190–1·600)</td>
    <td align="left">1·170 (0·640–2·360)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>The low and high tiers of seropositive participants are differentiated at the 1·8 IU/ml or more threshold. NA=not applicable.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
